Skip to main content

Table 5 Recurrence rates of HZ (per 100 persons - year), overall and by age groups and IC condition

From: Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014

IC condition

Recurrence rate of HZ per 100 PY (95% CI)

18–29

30–39

40–49

50–59

60–69

70–79

≥ 80

Overall

Population

0.99 (0.9–1.09)

1.13 (1.05–1.21)

1.19 (1.11–1.27)

1.31 (1.25–1.38)

1.7 (1.63–1.77)

2.2 (2.12–2.28)

2.71 (2.6–2.83)

1.66 (1.63–1.69)

IC-free cohort

0.93 (0.84–1.02)

1.08 (1–1.16)

1.1 (1.02–1.18)

1.23 (1.16–1.3)

1.62 (1.55–1.7)

2.09 (2–2.18)

2.62 (2.49–2.75)

1.56 (1.53–1.59)

IC cohort

1.88 (1.44–2.42)

1.63 (1.32–1.99)

1.87 (1.6–2.18)

1.81 (1.61–2.03)

2.08 (1.9–2.27)

2.69 (2.48–2.92)

3.13 (2.84–3.44)

2.28 (2.18–2.38)

HSCT

7.38 (1.52–21.56)

2.33 (0.28–8.4)

5.05 (2.18–9.95)

5.39 (2.87–9.22)

5.48 (3.07–9.04)

13.84 (4.49–32.31)

 

5.5 (4.03–7.34)

SOT

2.83 (0.58–8.26)

2.87 (1.15–5.92)

3.12 (1.7–5.23)

2.94 (1.94–4.28)

2.62 (1.8–3.68)

3.55 (2.38–5.1)

3.27 (1.74–5.59)

3.01 (2.5–3.58)

HN

3.32 (1.93–5.31)

1.89 (1.01–3.23)

2.04 (1.21–3.23)

3.27 (2.45–4.27)

3.08 (2.42–3.85)

4.16 (3.39–5.04)

4.03 (3.08–5.18)

3.35 (3.01–3.73)

SON

1.88 (0.39–5.5)

2.32 (1.27–3.89)

1.82 (1.23–2.58)

1.82 (1.49–2.2)

2.04 (1.78–2.33)

2.46 (2.19–2.75)

3.18 (2.81–3.58)

2.37 (2.22–2.53)

NEOPLASIAS

2.93 (1.79–4.52)

1.99 (1.3–2.91)

1.91 (1.41–2.52)

2 (1.69–2.36)

2.17 (1.92–2.43)

2.67 (2.42–2.95)

3.24 (2.89–3.62)

2.5 (2.36–2.64)

HIV

3.53 (1.3–7.69)

1.99 (1.11–3.28)

3.01 (2.22–3.99)

3.96 (2.61–5.76)

4.76 (2.38–8.52)

8.39 (2.73–19.59)

0 (0–48.47)

3.2 (2.63–3.85)

AUTOIMMUNE

1.65 (1.19–2.24)

1.48 (1.13–1.9)

1.66 (1.33–2.05)

1.62 (1.37–1.91)

2.1 (1.84–2.4)

2.84 (2.5–3.21)

3.1 (2.6–3.66)

2.12 (1.98–2.26)

RA

1.57 (0.19–5.67)

1.49 (0.48–3.47)

2.06 (1.18–3.35)

1.68 (1.12–2.43)

2.58 (2–3.28)

2.6 (1.99–3.34)

3.33 (2.42–4.48)

2.43 (2.12–2.77)

SLE

0 (0–5.28)

2.73 (0.89–6.37)

3.21 (1.39–6.33)

2.97 (1.42–5.46)

3.23 (1.48–6.13)

1.3 (0.16–4.69)

4.01 (0.83–11.71)

2.75 (1.93–3.79)

IBD

1.95 (0.71–4.24)

2.19 (1.16–3.74)

1.58 (0.82–2.77)

1.65 (0.94–2.68)

2.5 (1.64–3.63)

3.49 (2.3–5.07)

4.73 (2.97–7.16)

2.48 (2.06–2.96)

PSORIASIS

1.64 (1.06–2.42)

1.36 (0.9–1.96)

1.28 (0.85–1.85)

1.46 (1.1–1.9)

1.71 (1.34–2.16)

2.39 (1.89–2.98)

2.88 (2.04–3.96)

1.77 (1.58–1.97)

MS

0 (0–9.86)

1.59 (0.19–5.73)

4.08 (1.5–8.87)

0 (0–2.08)

2.59 (0.71–6.64)

2.89 (0.35–10.44)

0 (0–37.33)

1.94 (1.06–3.26)

AT

0 (0–9.6)

2.34 (0.28–8.45)

0.57 (0.01–3.16)

1.75 (0.71–3.61)

1.8 (0.66–3.92)

2.5 (0.81–5.84)

2.97 (0.61–8.69)

1.8 (1.15–2.68)

  1. CI Confidence interval, IC immunocompromised, HSCT haematopoietic stem cell transplant, SOT solid organ transplantation, HN haematological neoplasia, SON solid organ neoplasia, NEOPLASIAS neoplasias overall, HIV human immunodeficiency virus, AUTOIMMUNE RA rheumatoid arthritis, SLE systemic lupus erythematosus, IBD Inflammatory bowel disease, MS multiple sclerosis, AT autoimmune thyroiditis, AUTOIMMUNE immunodeficiency disorders and autoimmune diseases overall (See supplementary Table 1)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us